Although the transduction efficiencies of the CD19/CD22 Bicistronic Bi-CAR T-cell product [32] were much lower than those of CD19/CD22 Loop Bi-CAR T-cell product [34] in patients with ALL, survival was better in the former. This evidence concerns the gene CD22 and acute lymphoblastic leukemia.